NovaBay Pharmaceuticals, Inc.
NBY
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$1.36
FAIR PRICE
$0.94
MARGIN
$0.42
P/E Ratio
2.0x
Div. Yield
N/A
ROE
108.9%
Market Cap
$31M
Small-cap
COMING SOON
Get notified when NBY's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Michael Kazley
COUNTRY
US
HEADQUARTERS
EmeryVille
SECTOR
Healthcare
EXCHANGE
AMEX
METHODOLOGY
How we calculate NBY's fair price
NovaBay Pharmaceuticals, Inc.'s fair price of $0.94 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%). At the current market price of $1.36, NBY trades 30.9% above its calculated fair value. The stock's P/E of 2.0x is a key input in the relative valuation component.
DCF MODEL · 50%
Discounted cash flow analysis based on projected free cash flows, discounted at a rate reflecting NBY's risk profile.
RELATIVE · 30%
Comparing NBY's valuation multiples against Healthcare peers.
ANALYST · 20%
Aggregated analyst price targets for NBY, weighted by recency and analyst accuracy.
POWERED BY BULIOS
Get full analysis, financials, and AI insights for NBY.
Explore on BuliosFAQ
What is the fair price of NBY?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for NovaBay Pharmaceuticals, Inc. is $0.94. At the current market price of $1.36, NBY trades 30.9% above its calculated fair value.
Is NBY overvalued or undervalued?+
NovaBay Pharmaceuticals, Inc. is currently overvalued based on our valuation model. The stock trades at $1.36, which is 30.9% above the fair price of $0.94. The P/E ratio of 2.0x is a key metric in the valuation.
How often is NBY's fair price updated?+
We update fair price calculations for NBY daily after market close. The current fair price of $0.94 incorporates the latest market data and sector multiples.
What factors affect NBY's fair price calculation?+
NBY's fair price of $0.94 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 2.0x, ROE of 108.9%.
Is NBY a good buy right now?+
At $1.36, NBY trades 30.9% above our fair value estimate of $0.94. The stock is currently overvalued. ROE stands at 108.9% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does NBY pay dividends?+
NBY does not currently pay a dividend.